Intas Eyes Biosimilar Lucentis, Avastin To Boost Oncology Presence
This article was originally published in The Pink Sheet Daily
Executive Summary
Intas is bracing up for a sizable position in the Indian biosimilars market. Opportunities are large with growing patient numbers and scant supplies of affordable medicines, which are helping steer the company to growth rates upwards of 30%.